Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors
- PMID: 11698294
- DOI: 10.1182/blood.v98.10.3082
Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors
Abstract
Rearrangements of the c-myc oncogene have been found in most plasmacytomas induced in mice and human myeloma cell lines (HMCLs) analyzed so far. However, neither induced mouse plasmacytomas nor HMCLs represent relevant models for human multiple myeloma (MM). To evaluate the incidence of c-myc rearrangements in human plasma cell dyscrasias, sets of probes were generated to allow direct assessment of c-myc translocations on interphase plasma cells by using fluorescence in situ hybridization. After validation of these probes, a large cohort of patients with either newly diagnosed MM (n = 529), relapsed MM (n = 58), primary plasma cell leukemia (PCL; n = 23), monoclonal gammopathy of undetermined significance (n = 65), or smoldering MM (n = 24) were analyzed. C-myc rearrangements were identified in 15% of patients with MM or primary PCL, independently of the stage of the disease (ie, diagnosis or relapse and MM or primary PCL). Analysis of the 2 main translocations observed on karyotyping, ie, t(8;14) and t(8;22), revealed that these specific translocations represented only 25% (23 of 91) of c-myc rearrangements. c-myc rearrangements were then correlated with several other patients' characteristics: illegitimate IgH recombinations, chromosome 13 deletions, and serum beta2-microglobulin levels. The only significant correlation was with a high beta2-microglobulin level (P =.002), although a trend for association with t(4;14) was observed (P =.08). Thus, c-myc rearrangement analysis in patients with MM revealed a strikingly lower incidence than that in HMCLs and plasmacytomas induced in mice, indicating that data obtained with these models cannot be directly extrapolated to human MM.
Similar articles
-
Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context.Haematologica. 2009 Dec;94(12):1708-13. doi: 10.3324/haematol.2009.011064. Haematologica. 2009. PMID: 19996118 Free PMC article.
-
The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization.Blood. 1997 Jul 15;90(2):526-34. Blood. 1997. PMID: 9226151
-
High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies.Cancer Res. 1998 Dec 15;58(24):5640-5. Cancer Res. 1998. PMID: 9865713
-
[Genetic abnormalities in multiple myeloma: role in oncogenesis and impact on survival].Rev Med Interne. 2007 Oct;28(10):677-81. doi: 10.1016/j.revmed.2007.04.013. Epub 2007 May 25. Rev Med Interne. 2007. PMID: 17559979 Review. French.
-
Distinguishing primary and secondary translocations in multiple myeloma.DNA Repair (Amst). 2006 Sep 8;5(9-10):1225-33. doi: 10.1016/j.dnarep.2006.05.012. Epub 2006 Jul 10. DNA Repair (Amst). 2006. PMID: 16829212 Review.
Cited by
-
Complex karyotype determined using conventional cytogenetic analysis is a poor prognostic factor in patients with multiple myeloma.J Clin Exp Hematop. 2024;64(1):10-20. doi: 10.3960/jslrt.23047. J Clin Exp Hematop. 2024. PMID: 38538316 Free PMC article.
-
Cytogenetic Profile in Monoclonal Gammopathy of Undetermined Significance, Smoldering and Symptomatic Multiple Myeloma: A Study of 1087 Patients with Highly Purified Plasma Cells.Cancers (Basel). 2023 Dec 2;15(23):5690. doi: 10.3390/cancers15235690. Cancers (Basel). 2023. PMID: 38067393 Free PMC article.
-
Proteasome Inhibitors Silence Oncogenes in Multiple Myeloma through Localized Histone Deacetylase 3 (HDAC3) Stabilization and Chromatin Condensation.Cancer Res Commun. 2022 Dec;2(12):1693-1710. doi: 10.1158/2767-9764.crc-22-0255. Epub 2022 Dec 27. Cancer Res Commun. 2022. PMID: 36846090 Free PMC article.
-
Ultrafast prediction of somatic structural variations by filtering out reads matched to pan-genome k-mer sets.Nat Biomed Eng. 2023 Jul;7(7):853-866. doi: 10.1038/s41551-022-00980-5. Epub 2022 Dec 19. Nat Biomed Eng. 2023. PMID: 36536253
-
A personalized molecular approach in multiple myeloma: the possible use of RAF/RAS/MEK/ERK and BCL-2 inhibitors.Explor Target Antitumor Ther. 2022;3(4):463-479. doi: 10.37349/etat.2022.00095. Epub 2022 Aug 31. Explor Target Antitumor Ther. 2022. PMID: 36071980 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical